Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property

Principal signs R&D deal with University of Oxford

PTEC · Price

Executive Summary

  • Principal Technologies Inc. entered into a research and development agreement with the University of Oxford to develop and test its thermal sensor technology for medical applications, including cancer diagnosis and treatment.
  • The company announced the divestiture of its majority stake (reducing ownership from 80% to 20%) in its Austrian subsidiary, E&E CRO Consulting GmbH, to the subsidiary's management for nominal value.
  • The divestiture is subject to corporate and regulatory approvals, including acceptance by the TSX Venture Exchange.

Key Details

  • R&D Agreement: Principal Technologies has entered into an agreement with the University of Oxford to develop and test the thermal sensor, which is the subject of the company's long-term license with the university.
  • Applications: The development focuses on at least seven proposed medical applications of the Oxford proprietary heat-sensing technology, with a main focus on cancer diagnosis and treatment.
  • Divestiture Structure: Principal Technologies is reducing its stake in E&E CRO Consulting GmbH from 80% to 20%.
  • Transaction Consideration: The remaining shares are being sold to the management of E&E CRO for their nominal value.
  • Rationale: The decision follows a review of operations and an increasing focus on the company's own research and development activities.
  • Subsidiary Role: E&E CRO advises healthcare companies on how to efficiently conduct clinical studies.
  • Conditions Precedent: Completion of the E&E CRO disposition is subject to the receipt of all requisite corporate and regulatory approvals, including acceptance of the TSX Venture Exchange.

Notable Quotes

  • "We are excited about the development phase of the thermal sensor," said Principal chief executive officer Jerry Trent. "There are at least seven proposed medical applications of the Oxford proprietary heat-sensing technology and the successful development of these applications has become a main focus of our organization going forward."
Read the original news release →

More from Principal Technologies Inc